Department of Anesthesiology, University Hospital Duesseldorf, Moorenstrasse 5, 40225 Duesseldorf, Germany.
Department of Trauma, Hand, Plastic and Reconstructive Surgery, Translational and Experimental Trauma Research, University Hospital Ulm, Ulm University, Albert-Einstein-Allee 23, 89081 Ulm, Germany.
Int J Mol Sci. 2023 Dec 23;25(1):262. doi: 10.3390/ijms25010262.
Recent studies observed, despite an anti-hyperlipidaemic effect, a positive impact of fibrates on septic conditions. This study evaluates the effects of gemfibrozil on microcirculatory variables, mitochondrial function, and lipid peroxidation levels with regard to its potential role as an indicator for oxidative stress in the colon and liver under control and septic conditions and dependencies on PPARα-mediated mechanisms of action. With the approval of the local ethics committee, 120 Wistar rats were randomly divided into 12 groups. Sham and septic animals were treated with a vehicle, gemfibrozil (30 and 100 mg/kg BW), GW 6471 (1 mg/kg BW, PPARα inhibitor), or a combination of both drugs. Sepsis was induced via the colon ascendens stent peritonitis (CASP) model. Then, 24 h post sham or CASP surgery, a re-laparotomy was performed. Measures of vital parameters (heart rate (HR), mean arterial pressure (MAP), and microcirculation (µHbO)) were recorded for 90 min. Mitochondrial respirometry and assessment of lipid peroxidation via a malondialdehyde (MDA) assay were performed on colon and liver tissues. In the untreated sham animals, microcirculation remained stable, while pre-treatment with gemfibrozil showed significant decreases in the microcirculatory oxygenation of the colon. In the CASP animals, µHbO levels in the colon and the liver were significantly decreased 90 min after laparotomy. Pre-treatment with gemfibrozil prevented the microcirculatory aberrations in both organs. Gemfibrozil did not affect mitochondrial function and lipid peroxidation levels in the sham or CASP animals. Gemfibrozil treatment influences microcirculation depending on the underlying condition. Gemfibrozil prevents sepsis-induced microcirculatory aberrances in the colon and liver PPARα-independently. In non-septic animals, gemfibrozil impairs the microcirculatory variables in the colon without affecting those in the liver.
最近的研究观察到,尽管纤维酸类药物具有抗高血脂作用,但它对感染性疾病仍有积极影响。本研究评估了吉非贝齐对微循环变量、线粒体功能和脂质过氧化水平的影响,以评估其作为控制和感染条件下结肠和肝脏氧化应激指标的潜力,以及对 PPARα 介导的作用机制的依赖性。在当地伦理委员会的批准下,将 120 只 Wistar 大鼠随机分为 12 组。假手术和感染动物分别给予载体、吉非贝齐(30 和 100mg/kgBW)、GW6471(1mg/kgBW,PPARα 抑制剂)或两种药物的组合。通过结肠升支支架腹膜炎(CASP)模型诱导感染。然后,在假手术或 CASP 手术后 24 小时,进行再次剖腹术。记录 90 分钟内的生命体征(心率(HR)、平均动脉压(MAP)和微循环(µHbO))。对结肠和肝脏组织进行线粒体呼吸测定和丙二醛(MDA)测定评估脂质过氧化。在未治疗的假手术动物中,微循环保持稳定,而吉非贝齐预处理显示结肠的微循环氧合明显降低。在 CASP 动物中,剖腹术后 90 分钟,结肠和肝脏的µHbO 水平显著降低。吉非贝齐预处理可防止两个器官的微循环异常。吉非贝齐对 sham 或 CASP 动物的线粒体功能和脂质过氧化水平没有影响。吉非贝齐的治疗会根据潜在的情况影响微循环。吉非贝齐可预防感染引起的结肠和肝脏的微循环异常,与 PPARα 无关。在非感染性动物中,吉非贝齐可损害结肠的微循环变量,但不影响肝脏的微循环变量。
Biochim Biophys Acta Bioenerg. 2022-2-1
Clin Kidney J. 2021-1-11
Curr Opin Anaesthesiol. 2021-4-1